



Epigenetics & cancer

Present by : Sanaz Zebardast
Under supervision : Dr . Gheibi


31 December 2016



contents


- Introduction
- Epigenetic & signaling pathways
- Epigenetic & integral protein
- Epigenetic & apoptosis
- X-inactivation
- Conclusion
- references

Chart Title




Introduction (1)

- Heritable alterations that are not due to changes in DNA sequence
- Alter DNA accessibility and chromatin structure
- Regulate patterns of gene expression
- Crucial for normal development and differentiation
- Crucial for regulation of pluripotency genes




(2)

Epigenetic mechanisms





Nucleosome



- The basic repeating unit of chromatin.
- It is made up by five histone proteins: H2A, H2B, H3, H4 as core histones and H1 as a linker.
- It provides the lowest level of compaction of double-strand DNA into the cell nucleus.
- It often associates with transcription.

1974: Roger Kornberg discovers nucleosome who won Nobel Prize in 2006.

Histone modifications matter




Histone tails are modified, this influences accessibility of the genomic DNA

Latham and Dent
Nat Struct Mol Biol 2007

Structure & Epigenetics of Euchromatin versus Heterochromatin


DNA methylation and histone modifications help to compartmentalize the genome into domains of different transcriptional potentials

Euchromatin



- High histone acetylation
- Low DNA methylation
- H3-K4 methylation

Heterochromatin



- Low histone acetylation
- Dense DNA methylation
- H3-K9 methylation

Histon modifying enzymes

Acetyltransferase	Substrates
HAT1	H4 (K5, K12)
GCN5, PCAF	H3 (K9, K14, K18)
CBP, P300	H3 (K14, K18), H4 (K5, K8), H2AK5, H2B (K12, K15)
TIP60/PLIP	H4 (K5, K8, K12, K16), H3K14
HBO1	H4 (K5, K8, K12)
Lysine methyltransferases	Substrates
SUV39H1-2	H3K9
G9a	H3K9
EuHMTase/GLP	H3K9
ESET/SETDB1	H3K9
CLL8	H3K9
MLL1-5	H3K4
SET1A-B	H3K4
ASH1	H3K4
SET2	H3K36
NSD1	H3K36
SYMD2	H3K36
DOT1	H3K79
Pr-SET7/8	H4K20
SUV420H1-2	H4K20

Deacetylases	Substrates
Sirt2-3	H4K16
Lysine demethylases	Substrates
LSD1/BHC110	H3 (K4, K9)
JHDM1a-b	H3K36
JHDM2a-b	H3K9
JMJD2A/JHDM3A, JMJD2B-C	H3 (K9, K36)
JMJD2D	H3K9
JARID1A-D	H3K4
UTX	H3K27
JMJD3	H3K27
Serine/threonine kinases	Substrates
Haspin	H3T3
MSK1-2	H3S28
CKII	H4S1
Mst1	H2BS14
Rsk2	H3S10
Ubiquitilases	Substrates
Bmi/Ring1a	H2AK119
RNF20/RNF40	H2BK120
Arginine methyltransferases	Substrates
CARM1	H3 (R2, R17, R26)
PRMT4	H4R3


(3)

Effector proteins


Histone modification	Binding modules	* Effector proteins (Target histone)
Methylation	Chromodomain	HP1 (H3K9), PC (H3K27), CHD1 (H3K4)
	Tudor	JMJD2A (H3K4)
	MBT	L3MBTL1 (H1bK26, H4K20)
	PHD	BPTF (H3K4), ING2 (H3K4)
	SRA	UHRF1 (H3K9)
Acetylation	Bromodomain	Rsc4 (H3K14), Bdf1 (H4K8), Taf1 (H4K16)
Phosphorylation	14-3-3	14-3-3 protein (H3S10)

* A few representative effector proteins containing the specified binding module are shown with the target histone modification recognized by them in parentheses.

Histone acetylation



Other nuclear proteins crucial for epigenetic modifications



(3)

DNA methylation & Epigenetic (3)

- In mammalian genome methylation occurs in C5
- Methylation patterns are stable and inheritable
- Reprogramming occurs in 2 developmental stages
- DNMT3A and DNMT3B are de novo methyltransferases
- DNMT1s are maintenance methyltransferases

Other DNMTs (3)

- Unlike DNMT1 & DNMT3A/B , DNMT2 has only catalytic domain
- DNMTL expresses only in germ cell for de novo methylation
- DNMTL modulates the catalytic activity of DNMT3A & DNMT3B


Maintenance of Cytosine Methylation

Establishment and maintenance




Passive Demethylation of 5-Methyl-Cytosine


Establishment and maintenance




Establishment and Maintenance of Cytosine Methylation



Regions of DNA methylation



RNA Interference (RNAi)




(4)

Wnt signaling pathway (5)

- Conserved pathway that has crucial regulation role
- Cell fate determination , cell migration , cell polarity , neural patterning and organogenesis during embryonic development
- Require for adult tissue maintenance
- Perturbations in it promote both human degenerative diseases and cancer
- Therapeutic reagents are aimed for controlling wnt signaling


Wnt signaling pathway



Wnt signaling pathway & Epigenetic (6)

- Activation of wnt signaling pathway in the leukemia
- The promoter methylation status of wnt antagonists (sFRP 2,4,5 & DKK1,3) has been analyzed
- Aberrant methylation of them was detected by MSP (methylation-specific polymerase chain reaction)
- Function of epigenetic regulation of wnt pathway in predicting relapse in a subgroup of AML


Msp analysis in AML (acute myeloid leukemia) cell lines (6)



Jak-stat signaling pathway (7)

- Regulates embryonic development
- In the control of processes such as stem cell maintenance , haematopoiesis & inflammatory response
- Aberrant activation confers malignant properties on cancer cells
- A productive strategy for drug development

JAK/STAT Pathway




Jak/STAT signaling pathway & epigenetic (8)

- SOCS1 and SHP1 negatively regulate Jak/STAT signaling pathway
- promoter hypermethylation is investigated in myeloma
- SHP1 : primarily express in hematopoietic cells & is tumor suppressor gene
- Socs1 : cytokine-inducible negative regulators of the cytokine signaling

Epigenetic role on integral proteins (9)

- Occludin is the first identified integral protein for tight junction (tj)
- Its long COOH-terminal domain receive and transmit cell survival signal
- Loss of tj –associated molecules correlate with tumor progression
- Occludin expression is silenced by CpG island hypermethylation
- Forced expression of occludin in cancer cells leads to acting apoptogenic factors




Epigenetic & apoptosis (10)


- Some hematopoietic disease (CLL) fails apoptosis B-cell
- Nuclear factor κ B (NF κ B) mediated expression of antiapoptotic molecules
- Glycogen synthase kinase-3B (GSK3B) regulates (NF κ B)
- They accumulate in the nucleus of CLL B cells

Epigenetic & apoptosis


- Pharmacologic inhibition of GSK-3 leads to decrease expression of Bcl-2 & XIAP
- Abrogating binding is through an epigenetic mechanism
- GSK-3 is a potential therapeutic target in the treatment of CLL



Epigenetic & X-chromosome Inactivation




- In X-inactivation (lyonization) one of the two copies of the X chromosome present in female mammals is inactivated.
- The inactive X chromosome is silenced by packaging in repressive heterochromatin.
- The choice of which X chromosome will be inactivated is random.
- Silencing initiated at Xic/XIC and spreads along chromosome.
- 5meC CpG DNA modification is observed in inactivated X chromosomes.
- 5meC binds transcriptional repressor MeCP2 (MethylC-binding Protein-2).
- MeCP2 binds Sin3 with RPD3 histone deacetylase.



Source: Jones et al. Nat.Genet. 19, 187 (1998)

Differences in the epigenome of monozygotic twins



The difference in the twins' epigenomes is what makes them become different when they are older

The epigenetic tags can have such an effect on the twins that one can develop a disease while the other is fine

When this situation occurs, researchers will try to pinpoint the environmental factors that are responsible for the disease

Fraga et al. PNAS, 2005

conclusion

- that differing amounts in methylation can play a role in an animal's behavior
- Failures in epigenetic are likely to play a role in the majority of cancer
- Since most of the studies on epigenetics have been conducted on rodents, it will be interesting to see if their conclusions carry over into humans

Thank You



References

1. Kusan C, Godmann M. Genetic and Epigenetic Mechanisms That Maintain Hematopoietic Stem Cell Function. *Stem cells international*. 2015 Dec 20;2016.
2. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin?. *Cancer cell*. 2012 Jul 10;22(1):9-20.
3. Kim JK, Samaranyake M, Pradhan S. Epigenetic mechanisms in mammals. *Cellular and molecular life sciences*. 2009 Feb 1;66(4):596-612.
4. Nishikura K. A short primer on RNAi: RNA-directed RNA polymerase acts as a key catalyst. *Cell*. 2001 Nov 16;107(4):415-8.
5. Komiya Y, Habas R. Wnt signal transduction pathways. *Organogenesis*. 2008 Apr 1;4(2):68-75.
6. Valencia A, Roman-Gomez J, Cervera J, Such E, Barragan E, Bolufer P, Moscardo F, Sanz GF, Sanz MA. Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia. *Leukemia*. 2009 Sep 1;23(9):1658-66.

References

7. Thomas SJ, Snowden JA, Zeidler MP, Danson SJ. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. *British journal of cancer*. 2015 Jul 28;113(3):365-71.
8. Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. *Blood*. 2004 Jun 15;103(12):4630-5
9. Osanai M, Murata M, Nishikiori N, Chiba H, Kojima T, Sawada N. Epigenetic silencing of occludin promotes tumorigenic and metastatic properties of cancer cells via modulations of unique sets of apoptosis-associated genes. *Cancer research*. 2006 Sep 15;66(18):9125-33.
10. Ougolkov AV, Bone ND, Fernandez-Zapico ME, Kay NE, Billadeau DD. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor κ B target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. *Blood*. 2007 Jul 15;110(2):735-42.